These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Houghton PJ; Germain GS; Harwood FC; Schuetz JD; Stewart CF; Buchdunger E; Traxler P Cancer Res; 2004 Apr; 64(7):2333-7. PubMed ID: 15059881 [TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer? Wiedmann M; Kreth F; Feisthammel J; Deininger M; Mössner J; Caca K Anticancer Drugs; 2003 Oct; 14(9):751-60. PubMed ID: 14551510 [TBL] [Abstract][Full Text] [Related]
8. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571). Hotfilder M; Lanvers C; Jürgens H; Boos J; Vormoor J Cancer Chemother Pharmacol; 2002 Aug; 50(2):167-9. PubMed ID: 12172985 [TBL] [Abstract][Full Text] [Related]
9. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. González I; Andreu EJ; Panizo A; Inogés S; Fontalba A; Fernández-Luna JL; Gaboli M; Sierrasesúmaga L; Martín-Algarra S; Pardo J; Prósper F; de Alava E Clin Cancer Res; 2004 Jan; 10(2):751-61. PubMed ID: 14760098 [TBL] [Abstract][Full Text] [Related]
10. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity. Merchant MS; Woo CW; Mackall CL; Thiele CJ J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322 [TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo. Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263 [TBL] [Abstract][Full Text] [Related]
13. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells. Yasuda A; Sawai H; Takahashi H; Ochi N; Matsuo Y; Funahashi H; Sato M; Okada Y; Takeyama H; Manabe T Mol Cancer; 2006 Oct; 5():46. PubMed ID: 17044945 [TBL] [Abstract][Full Text] [Related]
14. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Demetri GD Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773 [TBL] [Abstract][Full Text] [Related]
15. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy. Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. Huh WK; Sill MW; Darcy KM; Elias KM; Hoffman JS; Boggess JF; Alvarez RD; Long HJ; O'Malley DM; Birrer MJ Gynecol Oncol; 2010 May; 117(2):248-54. PubMed ID: 20189232 [TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Croom KF; Perry CM Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228 [TBL] [Abstract][Full Text] [Related]
19. Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571. Yoshitani K; Honoki K; Morishita T; Kido A; Miyauchi Y; Mii Y; Takakura Y In Vivo; 2003; 17(3):255-8. PubMed ID: 12929576 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]